



Article

# Korean Red Ginseng Plays an Anti-Aging Role by Modulating Expression of Aging-Related Genes and Immune Cell Subsets

Kun Kuk Shin <sup>1,†</sup>, Young-Su Yi <sup>2,†</sup>, Jin Kyeong Kim <sup>1</sup>, Haeyeop Kim <sup>1</sup>,  
Mohammad Amjad Hossain <sup>3</sup>, Jong-Hoon Kim <sup>3,\*</sup> and Jae Youl Cho <sup>1,\*</sup>

<sup>1</sup> Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Korea; shuka337@naver.com (K.K.S.); rosekim95@naver.com (J.K.K.); rlagoduq7283@naver.com (H.K.)

<sup>2</sup> Department of Life Sciences, Kyonggi University, Suwon 16227, Korea; ysyi@kgu.ac.kr

<sup>3</sup> Department of Veterinary Physiology, College of Medicine, Chonbuk National University, Iksan 54596, Korea; mamjadh2@gmail.com

\* Correspondence: jhkim1@chonbuk.ac.kr (J.-H.K.); jaecho@skku.edu (J.Y.C.);  
Tel.: +82-63-270-2563 (J.-H.K.); +82-31-290-7876 (J.Y.C.)

† These authors are equally contributed.

Academic Editor: Deok Chun Yang

Received: 8 March 2020; Accepted: 25 March 2020; Published: 25 March 2020



**Abstract:** Despite previous reports of anti-aging effects of Korean red ginseng (KRG), the underlying mechanisms remain poorly understood. Therefore, this study investigated possible mechanisms of KRG-mediated anti-aging effects in aged mice. KRG significantly inhibited thymic involution in old mice. Interestingly, KRG only increased protein expression, but not mRNA expression, of aging-related genes Lin28a, GDF-11, Sirt1, IL-2, and IL-17 in the thymocytes of old mice. KRG also modulated the population of some types of immune cells in old mice. KRG increased the population of regulatory T cells and interferon-gamma (IFN- $\gamma$ )-expressing natural killer (NK) cells in the spleen of old mice, but serum levels of regulatory T cell-specific cytokines IL-10 and TGF- $\beta$  were unaffected. Finally, KRG recovered mRNA expression of Lin28a, GDF-11, and Sirt1 artificially decreased by concanavalin A (Con A) in both thymocytes and splenocytes of old mice without cytotoxicity. These results suggest that KRG exerts anti-aging effects by preventing thymic involution, as well as modulating the expression of aging-related genes and immune cell subsets.

**Keywords:** korean red ginseng; anti-aging; thymic involution; aging-related genes; immune cell population

## 1. Introduction

Aging is a biological process characterized by progressive alteration of body tissues, an inability to functionally adapt, and the accumulation of deficits at various organs, leading to a decline in physiological function, age-related diseases, and death [1–3]. Aging also involves gradual deterioration of the immune system in the body, known as immunosenescence, which is the result of inflammaging (an imbalance between inflammatory and anti-inflammatory responses) [4,5], oxidative stress [6], remodeling of the immune system [7], apoptosis and upregulation of pro-inflammatory cytokines [7], and differential expression of aging-related genes [8].


*Panax ginseng*, also known as Korean ginseng, is a perennial plant that has long been used as a traditional herbal medicine in the world, especially in far-eastern Asian countries like Korea, China, and Japan [9–11]. Since fresh ginseng easily decays at room temperature, ginseng is processed to red ginseng by steaming and drying to a dark red color. Korean red ginseng (KRG) has been demonstrated to have higher pharmacological activities and lower side effects compared to fresh ginseng [12]. Many studies

have revealed that KRG has a critical impact on various biological and disease conditions through immune-boosting, antioxidant, neuroprotective, anti-diabetic, hepatoprotective, autophagy-regulatory, and anti-cancer effects [13–16]. Accumulating evidence indicates that KRG also has anti-aging effects and can extend the life span of organisms [17–20], but the underlying molecular and cellular mechanisms remain poorly understood. Therefore, this study aimed to investigate KRG-mediated anti-aging effects and the associated underlying molecular and cellular mechanisms in aged mice.

## 2. Results and Discussion

### 2.1. KRG Inhibited Aging-Related Thymic Involution

Aging induces the gradual deterioration of the immune system, known as immunosenescence, which results in the alteration of immune functions, including immune deficiency, autoimmunity, and an imbalance of inflammation [21–23]. One of the hallmarks of immunosenescence is apoptosis-induced thymic involution, which reduces the T-cell repertoire and leads to accumulation of effector T-cells and autoimmunity [24,25]. Therefore, the effect of KRG on aging-related thymic involution was evaluated in old mice. As expected, thymus size was markedly smaller in old mice (17 months old) compared to young mice (2 months old); however, thymus size in KRG-administered old mice was comparable to that of young mice (Figure 1a). Metformin, a medication for the treatment of type 2 diabetes, has been demonstrated to play an anti-aging role by preventing oxidative stress-induced DNA damage and inflammation, which improves aging outcomes [26,27]. Similar to KRG, thymic size in metformin-treated old mice was as big as that in young mice (Figure 1a). Overall, KRG and metformin significantly inhibited the decrease in thymic length seen in untreated old mice (Figure 1b). These results suggest that KRG plays an anti-aging role by inhibiting aging-related thymic involution in mice.



**Figure 1.** Korean red ginseng (KRG) inhibited aging-related thymic involution. (a) Thymi were excised from young (2 months old) and old (17 months old) mice orally dosed with KRG (200 mg/kg) or metformin (200 mg/kg) and photographed. (b) Thymic size (length) of the mice ( $n = 6$ ) was measured and plotted. Scale bar = 5 mm. ## $p < 0.01$  compared to vehicle-administered control young mice, and \* $p < 0.05$  compared to vehicle-administered control old mice.

## 2.2. KRG Altered Protein Expression, But Not mRNA Expression of Aging-Related Genes in Aged Mice

The anti-aging effect of KRG was next investigated by evaluating the expression of aging-related genes in old mice. Lin28a, an RNA-binding protein that is highly expressed in embryonic stem cells, helps generate energy for cellular functions through glycolytic metabolism, and a decrease in its expression is a hallmark of the aging process [28]. Growth Differentiation Factor-11 (GDF-11), a member of the transforming growth factor family, has been reported as a rejuvenation factor that reverses age-related decline of tissue functions [29–32] and is highly expressed in young animals [33]. Sirtuin 1 (SIRT1), an NAD-dependent deacetylase, helps prevent age-related DNA damage and telomere shortening by inducing telomerase reverse transcriptase activity [34,35]. Knockdown of its expression in young cells induces cellular senescence and proliferation, whereas, its overexpression in aged cells reverses senescence phenotypes [36]. Taken together, these findings led to an investigation into the effect of KRG on the expression of aging-related genes in the thymus of old mice by quantitative real-time PCR analysis. mRNA expression levels of these genes in thymocytes were neither different between young and old mice nor statistically changed by KRG in the thymocytes of old mice (Figure 2a–c). Interestingly, unlike mRNA expression, KRG induced protein expression of Lin28a, GDF-11, and Sirt1 in the thymocytes of old mice (Figure 2d). The reason why KRG induced protein expression of these genes only and not mRNA expression is not clear, and requires further investigation.


Interleukin (IL)-2 is a key molecule produced by helper T cells that induces the differentiation and function of many types of immune cells [37,38]. In the thymus, IL-2 promotes the differentiation of regulatory T cells to prevent autoimmunity [39–42]. IL-17, a cytokine also produced by helper T cells, plays a role in promoting host defense, pro-inflammatory, and allergic responses [43]. Studies have reported that the expression of IL-2 decreases while that of IL-17 increases during the aging process [44–46]. Given this evidence, the effect of KRG on the expression of these cytokines in the thymus of old mice was investigated by quantitative real time PCR analysis. KRG did not affect mRNA expression of either IL-2 or IL-17 in the thymocytes of old mice (Figure 2e,f).

In summary, these results suggest that although KRG plays an anti-aging role by preventing thymic involution (Figure 1), KRG only increases protein expression, but not mRNA expression, of aging-related genes such as Lin28a, GDF-11, and Sirt1, as well as aging-related cytokines such as IL-2 and IL-17 in the thymus of old mice. These results raise the necessity of investigating how KRG inhibits thymic involution through mechanisms other than altering the expression of aging-related genes and cytokines in the aged thymus. Moreover, further research on the effects of KRG on the expression of these aging-related genes in other types of immune organs and cells that play critical roles in the aging process is needed.

## 2.3. KRG Regulated the Population of Thymic and Splenic Immune Cells in Aged Mice

Previous studies demonstrated that immune system impairment with the aging process is associated with alterations in the quantity of various immune cell subsets, such as CD4 T cells, CD8 T cells, and natural killer (NK) cells [47–50]. Accordingly, the effect of KRG on alterations to the quantity of various immune cell subsets was next investigated by flow cytometry.

Regulatory T cells are suppressive T cells with an immunosuppressive function that helps maintain immune tolerance to self-antigens and prevents autoimmunity. The effect of aging on the pool of regulatory T cells is still poorly understood, hence, the effect of KRG on the numbers of regulatory T cells was first evaluated in the primary lymphoid organs of the thymus and spleen of old mice. The number of CD25<sup>+</sup>/Foxp3<sup>+</sup> regulatory T cells in both the thymus (Figure 3a) and spleen (Figure 3b) was not statistically different between young and old mice. However, KRG significantly increased the quantity of splenic regulatory T cells (Figure 3b), but not thymic regulatory T cells, in old mice (Figure 3a). These results might indicate that KRG inhibits signs of immunosenescence, such as autoimmunity and inflammaging, by increasing the number of regulatory T cells in the spleen where T cells are activated, but not in the thymus where T cells mature and differentiate. KRG may increase the population of regulatory T cells by promoting their function rather than their differentiation.



**Figure 2.** KRG did not alter the expression of aging-related genes in aged mice. (a–c) mRNA expression of Lin28a, GDF-11, and Sirt1 in the thymocytes of young and old mice dosed with KRG (200 mg/kg) or metformin (200 mg/kg) was determined using quantitative real-time PCR. (d) Protein expression of Lin28a, GDF-11, and Sirt1 in the thymocytes of young and old mice dosed with KRG (200 mg/kg) or metformin (200 mg/kg) was determined using Western blot analysis. (e,f) mRNA expression of IL-2 and IL-17 in the thymocytes of young and old mice dosed with KRG (200 mg/kg) or metformin (200 mg/kg) was determined using quantitative real-time PCR.

NK cells are a type of cytotoxic immune cell that plays a critical role in the elimination of pathogen-infected cells, and the effect of KRG on the NK cell population was next evaluated in the spleen of old mice. Total numbers of splenic NK1.1<sup>+</sup> NK cells were reduced in old mice compared to young mice, but were not changed by KRG in old mice (Figure 3c). We further examined the effect of KRG on the population of functional NK cells in the spleen of old mice. The population of functional splenic NK cells expressing interferon-gamma (IFN- $\gamma$ ; NK1.1<sup>+</sup>/IFN- $\gamma$ <sup>+</sup>) was increased in old mice compared to young mice and also increased by KRG in old mice (Figure 3c). These results indicate that KRG promotes immunity in old mice by inducing NK cell function rather than increasing the NK cell population.

Macrophages are innate immune cells that eliminate pathogens by phagocytosis, and the effect of KRG on the macrophage population was evaluated in the spleen of old mice. No difference in the population of splenic F4/80<sup>+</sup> macrophages was observed between young and old mice, and KRG did not alter the population of splenic macrophages in old mice (Figure 3d).

Dendritic cells are antigen-presenting cells that link innate and adaptive immunity, and the effect of KRG on the population of dendritic cells was further evaluated in the spleen of old mice. The population of splenic CD11c<sup>+</sup> dendritic cells was increased in old mice compared to young mice, but was not altered by KRG in old mice (Figure 3e).

CD4 T cells, also known as helper T cells, are adaptive immune cells that activate other types of immune cells by releasing various cytokines, and the effect of KRG on the population of CD4 T cells was evaluated in the spleen of old mice. The population of splenic CD4<sup>+</sup> T cells was slightly smaller in old mice compared to young mice, but was not altered by KRG in old mice (Figure 3f).

Taken together, these results suggest that KRG reduces the risks of immunosenescence, such as autoimmunity and inflammaging, by increasing the population of splenic regulatory T cells and promotes immunity by inducing the function of splenic NK cells through increasing the population of the functionally active IFN- $\gamma$ -expressing splenic NK cells in old mice. Further studies investigating the molecular mechanisms by which KRG regulates the populations of these immune cells are warranted.






Figure 3. Cont.



**Figure 3.** KRG regulated the population of thymic and splenic immune cells in aged mice. (a) Total thymic cells were stained for CD25 and Foxp3, and CD25<sup>+</sup>/Foxp3<sup>+</sup> cells were analyzed using flow cytometry and plotted. (b) Total splenic cells were stained for CD25 and Foxp3, and CD25<sup>+</sup>/Foxp3<sup>+</sup> cells were analyzed using flow cytometry and plotted. (c) Total splenic cells were stained for NK1.1 and IFN- $\gamma$ , and NK1.1<sup>+</sup>/IFN- $\gamma$ <sup>+</sup> cells were analyzed using flow cytometry and plotted. (d) Total splenic cells were stained for F4/80 and NK1.1, and F4/80<sup>+</sup> cells were analyzed using flow cytometry and plotted. (e) Total splenic cells were stained for CD11c and NK1.1, and CD11c<sup>+</sup> cells were analyzed using flow cytometry and plotted. (f) Total splenic cells were stained for CD4 and CD3, and CD4<sup>+</sup> cells were analyzed using flow cytometry and plotted. <sup>#</sup> $p < 0.05$ , <sup>##</sup> $p < 0.01$  compared to vehicle-administered control young mice, and <sup>\*</sup> $p < 0.05$  compared to vehicle-administered control old mice.

#### 2.4. KRG Did Not Alter the Production of Regulatory T Cell-Specific Cytokines IL-10 and TGF- $\beta$ in Aged Mice


Since KRG increased the population of splenic CD25<sup>+</sup>/Foxp3<sup>+</sup> regulatory T cells in old mice (Figure 3b), the effect of KRG on the production of regulatory T cell-specific cytokines, IL-10 and tumor growth factor- $\beta$  (TGF- $\beta$ ) [51–53] was next investigated in old mice. Serum levels of IL-10 and TGF- $\beta$  were not significantly different between young and old mice (Figure 4a,b). Interestingly, although KRG increased the population of splenic regulatory T cells in old mice (Figure 3b), it did not significantly induce the production of IL-10 and TGF- $\beta$  (Figure 4a,b). The exact reason for this observation is unclear. However, it may be that KRG only increases the population of splenic regulatory T cells, but does not stimulate the production of regulatory T cell-specific cytokines under normal conditions. Under conditions that activate regulatory T cells, however, KRG might modulate not only the population of regulatory T cells, but also the production of regulatory T cell-specific cytokines IL-10 and TGF- $\beta$ . This possibility needs further investigation.



**Figure 4.** KRG did not alter the production of regulatory T cell-specific cytokines IL-10 and TGF- $\beta$  in aged mice. Serum level of (a) IL-10 and (b) TGF- $\beta$  in young and old mice dosed with KRG (200 mg/kg) or metformin (200 mg/kg) was determined using ELISA.

#### 2.5. KRG Increased the Expression of Aging-Related Genes in Con A-Stimulated T Cells in Aged Mice

Aging is strongly associated with the decline of functionally active T cells and the accumulation of T cells hyporesponsive to the effects of activators and mitogens such as concanavalin A (Con A) [54,55]. Therefore, the effect of KRG on the expression of aging-related genes in Con A-stimulated thymocytes and splenocytes of old mice was investigated by quantitative real-time PCR analysis. First, the cytotoxicity of KRG on Con A-stimulated thymocytes and splenocytes of old mice was evaluated, and KRG showed no cytotoxicity on these cells at the doses tested in this study (12.5–200  $\mu$ g/mL) (Figure 5a). The effect of KRG on the expression of aging-related genes Lin28a, GDF-11, and Sirt1 in Con A-stimulated thymocytes of old mice was next evaluated. KRG dose-dependently increased mRNA expression of Lin28a (Figure 5b), GDF-11 (Figure 5c), and Sirt1 (Figure 5d) that was downregulated by Con A in the thymocytes of old mice. Similar results were observed in splenocytes. KRG dose-dependently increased mRNA expression of Lin28a (Figure 5e), GDF-11 (Figure 5f), and Sirt1 (Figure 5g) that was downregulated by Con A in the splenocytes of old mice. These results are consistent with findings that KRG increased protein expression of these genes in the thymocytes of old mice (Figure 2d), but different than observations that KRG did not increase mRNA expression of these genes in non-stimulated thymocytes of old mice (Figure 2a–c). Why the effect of KRG on mRNA expression of these genes differed between non-stimulated and mitogen-stimulated thymocytes of old mice is unclear, and further study is needed to clarify.



**Figure 5.** KRG increased the expression of aging-related genes in Con A-stimulated T cells in aged mice. (a) Total thymocytes and splenocytes pretreated with Con A (5 µg/mL) for 30 min were treated with the indicated doses of KRG (0–200 µg/mL) for 24 h, and cell viability was determined using a conventional MTT assay. (b–d) mRNA expression of Lin28a, GDF-11, and Sirt1 genes in the thymocytes of old mice treated with Con A (5 µg/mL) and KRG (0–200 µg/mL) for 6 h was determined using quantitative real-time PCR. (e–g) mRNA expression of Lin28a, GDF-11, and Sirt1 genes in the splenocytes of old mice treated with Con A (5 µg/mL) and KRG (0–200 µg/mL) for 6 h was determined using quantitative real-time PCR. ## $p < 0.01$  compared to vehicle-treated control cells, and \* $p < 0.05$ , \*\* $p < 0.01$  compared to Con A-treated control cells.

All together, these results indicate that KRG, without cytotoxicity, can inhibit the decline of functionally active T cells and the accumulation of hyporesponsive T cells with age in the thymus and spleens of old mice by increasing the expression of aging-related genes that are expected to be downregulated during the aging process.



### 3. Materials and Methods

#### 3.1. Materials

Korean red ginseng (KRG) was purchased from Korea Ginseng Corp. (Daejeon, Korea), and the information on the composition of KRG was described in Table 1. C57BL/6J young mice (male, 2 months old) and old mice (male, 17 months old) were purchased from Dae Han Bio Link Co., Ltd. (Osong, Korea). Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS), streptomycin, penicillin, L-glutamate, and MuLV reverse transcriptase (RT) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Metformin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Con A, bovine serum albumin (BSA), and sodium azide were purchased from Sigma-Aldrich (St. Louis, MO, USA). TRI reagent<sup>®</sup> was purchased from Molecular Research Center Inc. (Cincinnati, OH, USA). Primers used for quantitative real-time polymerase chain reaction (PCR) were designed and synthesized at Bioneer Inc. (Daejeon, Korea). Antibodies used for Western blot and flow cytometry analyses were purchased from Cell Signaling Technology (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA). Enhanced chemiluminescence (ECL) reagent was purchased from AbFrontier Co., Ltd. (Seoul, Korea). IL-10 and TGF- $\beta$  enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems, Inc. (Minneapolis, MN, USA).

**Table 1.** Information of the composition of KRG (g).

Ingredient	Amount
Ginsenoside Rg1	
Ginsenoside Rb1	5.5 mg
Ginsenoside Rg3	
Carbohydrate	0.33 g

#### 3.2. Animal Husbandry and Experiments

C57BL/6J mice were caged with a 12-h light and dark cycle and fed a pelleted diet and tap water *ad libitum*. For animal experiments, mice (n = 7/group) were orally administered with either vehicle, KRG (200 mg/kg), or metformin (200 mg/kg) once a day for 30 days. The doses of KRG and metformin used in this study were determined as optimal doses based on the previous studies [56–60]. The mice were anaesthetized prior to tissue excision and blood collection by the intraperitoneal injection with ketamine (100 mg/kg) and xylazine (10 mg/kg) according to the previous study [61]. All animal studies were conducted according to the Institutional Animal Care and Use Committee of Sungkyunkwan University (Approved number: 2018-10-16-1). Thymi from each group of mice orally dosed with either KGR (200 mg/kg) or metformin (200 mg/kg) were excised and photographed to measure their size.

#### 3.3. Quantitative Real Time PCR

Mice were orally dosed with either KGR (200 mg/kg) or metformin (200 mg/kg). Total thymocytes and splenocytes isolated from the old mice were treated with Con A (5  $\mu$ g/mL) and the indicated doses of KGR (0–200  $\mu$ g/mL) for 6 h. Total RNA was isolated from total thymocytes and splenocytes using TRI reagent<sup>®</sup> according to the manufacturer's instructions. cDNA was synthesized from total RNA (1  $\mu$ g) using MuLV RT according to the manufacturer's instructions and used for quantitative real-time PCR to measure the expression levels of target genes. All primer sequences used for quantitative real-time PCR are listed in Table 2.

**Table 2.** Primer sequences used for quantitative real-time PCR in this study.

Targets		Sequences (5' → 3')
Lin28a	For	TCGGTGTCCAACCAGCAGTT
	Rev	GGCGGTCATAGACAGGAAGC
GDF-11	For	GATCCTGGACCTACACGACTTC
	Rev	GGCCTTCAGTACCTTTGTGAAC
Sirt1	For	CAGTGTTCATGGTTCCTTTGC
	Rev	CACCGAGGAACTACCTGAT
IL-2	For	TTAGGACAGCACAAAGTAAGCG
	Rev	TGAGCTGATGTTAGCTCCCTG
IL-17	For	GCTGACCCCTAAGAAACCCC
	Rev	GAAGCAGTTTGGGACCCCTT
GAPDH	For	CAATGAATACGGCTACAGCAAC
	Rev	AGGGAGATGCTCAGTGTGTTG

### 3.4. Western Blot Analysis

Mice were orally dosed with either KGR (200 mg/kg) or metformin (200 mg/kg). Total thymocytes and splenocytes isolated from old mice were treated with Con A (5 µg/mL) and the indicated doses of KGR (0–200 µg/mL) 24 h. Total thymocyte and splenocyte lysates were prepared by homogenization in cold lysis buffer (20 mM Tris HCl, pH 7.4, 2 mM EDTA, 2 mM ethyleneglycotetraacetic acid, 50 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1% Triton X-100, 10% glycerol, 10 mg/mL aprotinin, 10 mg/mL pepstatin, 1 mM benzimidazole, and 2 mM PMSF) at 4 °C for 30 min. Whole thymocyte and splenocyte lysates were subjected to Western blot analysis, and protein targets were detected using the antibodies specific for each target, as previously described [62].

### 3.5. Flow Cytometry Analysis

Mice were orally dosed with either KGR (200 mg/kg) or metformin (200 mg/kg). Total thymocytes and splenocytes from these mice were prepared and washed three times with cold PBS, followed by suspension in flow buffer (1% BSA, 0.1% sodium azide). The cell suspension was incubated with the indicated antibodies on ice for 30 min in the dark, and the fluorescence was detected using a CytoFLEX Flow Cytometer (Beckman Coulter Life Sciences, Indianapolis, IN, USA).

### 3.6. ELISA

Sera of each group of mice orally dosed with either KGR (200 mg/kg) or metformin (200 mg/kg) were collected from whole blood by centrifugation for 1 min. The sera were used for ELISA to measure the amounts of IL-10 and TGF-β in blood according to the manufacturer's instructions.

### 3.7. Cell Viability Assay

Total thymocytes and splenocytes were treated with Con A (5 µg/mL) and the indicated doses of KGR (0–200 µg/mL) for 24 h, and cell viability was determined by conventional MTT assay, as previously described [63].

### 3.8. Statistical Analysis

In this study, all data are presented as means ± standard error of the mean (S.E.M.) obtained from three independent experiments. Analysis of variance (ANOVA) with Scheffe's post hoc test or Kruskal-Wallis/Mann-Whitney tests were used to compare data and to assess the significance of group differences. All statistical analyses were conducted using an SPSS program (SPSS Inc., Chicago, IL, USA), and a *p* value less than 0.05 indicated statistical significance.

#### 4. Conclusions

Despite a number of studies investigating various pharmacological effects of KRG, only a small number of studies have investigated the anti-aging effect of KRG, and the underlying mechanism has not been clearly demonstrated yet. Therefore, this study aimed to investigate the KRG-mediated in vivo and ex vivo anti-aging effects and to unveil the underlying molecular and cellular mechanisms using the aged mice. KRG showed an in vivo anti-aging effect by suppressing the age-related thymic involution without the significant cytotoxicity, and this KRG-mediated anti-aging effect was achieved by increasing the expression of Lin28a, GDF-11, and SIRT1, as well as the population of the splenic regulatory T cells and IFN- $\gamma$ -expressing NK cells in the aged mice. In conclusion, these results suggest that KRG plays an anti-aging role by modulating the expression of the age-related genes and the population of the immune cell subsets in the aged mice.

**Author Contributions:** K.K.S., Y.-S.Y., J.-H.K., and J.Y.C. conceived and designed the experiments; K.K.S., J.K.K., H.K., and M.A.H. performed the experiments; K.K.S., Y.-S.Y., J.-H.K., and J.Y.C. analyzed the data; K.K.S., Y.-S.Y., J.-H.K., and J.Y.C. wrote the paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by a grant funded by the Korean Ginseng Society (2019 to J.Y.C.).

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

#### References

1. Titorenko, V.I. Molecular and Cellular Mechanisms of Aging and Age-related Disorders. *Int. J. Mol. Sci.* **2018**, *19*, 2049. [[CrossRef](#)]
2. Jayanthi, P.; Joshua, E.; Ranganathan, K. Ageing and its implications. *J. Oral Maxillofac. Pathol.* **2010**, *14*, 48–51. [[CrossRef](#)]
3. Christensen, K.; Doblhammer, G.; Rau, R.; Vaupel, J.W. Ageing populations: The challenges ahead. *Lancet* **2009**, *374*, 1196–1208. [[CrossRef](#)]
4. Zuo, L.; Prather, E.R.; Stetskiy, M.; Garrison, D.E.; Meade, J.R.; Peace, T.I.; Zhou, T. Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. *Int. J. Mol. Sci.* **2019**, *20*, 4472. [[CrossRef](#)] [[PubMed](#)]
5. Minciullo, P.L.; Catalano, A.; Mandraffino, G.; Casciaro, M.; Crucitti, A.; Maltese, G.; Morabito, N.; Lasco, A.; Gangemi, S.; Basile, G. Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity. *Arch. Immunol. Ther. Exp. (Warsz)* **2016**, *64*, 111–126. [[CrossRef](#)]
6. Kurek, K.; Plitta-Michalak, B.; Ratajczak, E. Reactive Oxygen Species as Potential Drivers of the Seed Aging Process. *Plants* **2019**, *8*, 174. [[CrossRef](#)] [[PubMed](#)]
7. Ventura, M.T.; Casciaro, M.; Gangemi, S.; Buquicchio, R. Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation. *Clin. Mol. Allergy* **2017**, *15*, 21. [[CrossRef](#)] [[PubMed](#)]
8. Sidler, C.; Woycicki, R.; Ilnytskyi, Y.; Metz, G.; Kovalchuk, I.; Kovalchuk, O. Immunosenescence is associated with altered gene expression and epigenetic regulation in primary and secondary immune organs. *Front. Genet.* **2013**, *4*, 211. [[CrossRef](#)] [[PubMed](#)]
9. Shin, B.K.; Kwon, S.W.; Park, J.H. Chemical diversity of ginseng saponins from *Panax ginseng*. *J. Ginseng Res.* **2015**, *39*, 287–298. [[CrossRef](#)]
10. Lee, J.I.; Park, K.S.; Cho, I.H. *Panax ginseng*: A candidate herbal medicine for autoimmune disease. *J. Ginseng Res.* **2019**, *43*, 342–348. [[CrossRef](#)]
11. Zhao, B.; Lv, C.; Lu, J. Natural occurring polysaccharides from *Panax ginseng* C. A. Meyer: A review of isolation, structures, and bioactivities. *Int. J. Biol. Macromol.* **2019**, *133*, 324–336. [[CrossRef](#)] [[PubMed](#)]
12. Lee, S.M.; Bae, B.S.; Park, H.W.; Ahn, N.G.; Cho, B.G.; Cho, Y.L.; Kwak, Y.S. Characterization of Korean Red Ginseng (*Panax ginseng* Meyer): History, preparation method, and chemical composition. *J. Ginseng Res.* **2015**, *39*, 384–391. [[CrossRef](#)]
13. Qomaladewi, N.P.; Kim, M.Y.; Cho, J.Y. Autophagy and its regulation by ginseng components. *J. Ginseng Res.* **2019**, *43*, 349–353. [[CrossRef](#)] [[PubMed](#)]
14. Ahuja, A.; Kim, J.H.; Kim, J.H.; Yi, Y.S.; Cho, J.Y. Functional role of ginseng-derived compounds in cancer. *J. Ginseng Res.* **2018**, *42*, 248–254. [[CrossRef](#)] [[PubMed](#)]

15. Kim, J.H.; Yi, Y.S.; Kim, M.Y.; Cho, J.Y. Role of ginsenosides, the main active components of *Panax ginseng*, in inflammatory responses and diseases. *J. Ginseng Res.* **2017**, *41*, 435–443. [[CrossRef](#)]
16. Mohanan, P.; Subramaniyam, S.; Mathiyalagan, R.; Yang, D.C. Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions. *J. Ginseng Res.* **2018**, *42*, 123–132. [[CrossRef](#)] [[PubMed](#)]
17. Lee, S.H.; Lee, H.Y.; Yu, M.; Yeom, E.; Lee, J.H.; Yoon, A.; Lee, K.S.; Min, K.J. Extension of *Drosophila* lifespan by Korean red ginseng through a mechanism dependent on dSir2 and insulin/IGF-1 signaling. *Aging (Albany NY)* **2019**, *11*, 9369–9387. [[CrossRef](#)] [[PubMed](#)]
18. Kopalli, S.R.; Cha, K.M.; Ryu, J.H.; Lee, S.H.; Jeong, M.S.; Hwang, S.Y.; Lee, Y.J.; Song, H.W.; Kim, S.N.; Kim, J.C.; et al. Korean red ginseng improves testicular ineffectiveness in aging rats by modulating spermatogenesis-related molecules. *Exp. Gerontol.* **2017**, *90*, 26–33. [[CrossRef](#)]
19. Park, S.; Kim, C.S.; Min, J.; Lee, S.H.; Jung, Y.S. A high-fat diet increases oxidative renal injury and protein glycation in D-galactose-induced aging rats and its prevention by Korea red ginseng. *J. Nutr. Sci. Vitaminol. (Tokyo)* **2014**, *60*, 159–166. [[CrossRef](#)]
20. Tian, C.; Kim, Y.J.; Lim, H.J.; Kim, Y.S.; Park, H.Y.; Choung, Y.H. Red ginseng delays age-related hearing and vestibular dysfunction in C57BL/6 mice. *Exp. Gerontol.* **2014**, *57*, 224–232. [[CrossRef](#)]
21. El-Naseery, N.I.; Mousa, H.S.E.; Noreldin, A.E.; El-Far, A.H.; Elewa, Y.H.A. Aging-associated immunosenescence via alterations in splenic immune cell populations in rat. *Life Sci.* **2020**, *241*, 117168. [[CrossRef](#)] [[PubMed](#)]
22. Salminen, A.; Kaarniranta, K.; Kauppinen, A. Immunosenescence: The potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency. *Cell. Mol. Life Sci.* **2019**, *76*, 1901–1918. [[CrossRef](#)] [[PubMed](#)]
23. Bischof, J.; Gartner, F.; Zeiser, K.; Kunz, R.; Schreiner, C.; Hoffer, E.; Burster, T.; Knippschild, U.; Zimecki, M. Immune Cells and Immunosenescence. *Folia Biol. (Praha)* **2019**, *65*, 53–63. [[PubMed](#)]
24. Palmer, S.; Albergante, L.; Blackburn, C.C.; Newman, T.J. Thymic involution and rising disease incidence with age. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 1883–1888. [[CrossRef](#)]
25. Odinokov, D.; Hamblin, M.R. Aging of lymphoid organs: Can photobiomodulation reverse age-associated thymic involution via stimulation of extrapineal melatonin synthesis and bone marrow stem cells? *J. Biophotonics* **2018**, *11*, e201700282. [[CrossRef](#)]
26. Valencia, W.M.; Palacio, A.; Tamariz, L.; Florez, H. Metformin and ageing: Improving ageing outcomes beyond glycaemic control. *Diabetologia* **2017**, *60*, 1630–1638. [[CrossRef](#)]
27. Glossmann, H.H.; Lutz, O.M.D. Metformin and Aging: A Review. *Gerontology* **2019**, *65*, 581–590. [[CrossRef](#)]
28. Docherty, C.K.; Salt, I.P.; Mercer, J.R. Lin28A induces energetic switching to glycolytic metabolism in human embryonic kidney cells. *Stem Cell Res. Ther.* **2016**, *7*, 78. [[CrossRef](#)]
29. Loffredo, F.S.; Steinhilber, M.L.; Jay, S.M.; Gannon, J.; Pancoast, J.R.; Yalamanchi, P.; Sinha, M.; Dall’Osso, C.; Khong, D.; Shadrach, J.L.; et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. *Cell* **2013**, *153*, 828–839. [[CrossRef](#)]
30. Katsimpardi, L.; Litterman, N.K.; Schein, P.A.; Miller, C.M.; Loffredo, F.S.; Wojtkiewicz, G.R.; Chen, J.W.; Lee, R.T.; Wagers, A.J.; Rubin, L.L. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. *Science* **2014**, *344*, 630–634. [[CrossRef](#)]
31. Sinha, M.; Jang, Y.C.; Oh, J.; Khong, D.; Wu, E.Y.; Manohar, R.; Miller, C.; Regalado, S.G.; Loffredo, F.S.; Pancoast, J.R.; et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. *Science* **2014**, *344*, 649–652. [[CrossRef](#)] [[PubMed](#)]
32. Li, L.; Wei, X.; Wang, D.; Lv, Z.; Geng, X.; Li, P.; Lu, J.; Wang, K.; Wang, X.; Sun, J.; et al. Positive effects of the young systemic environment and high GDF-11 levels on chondrocyte proliferation and cartilage matrix synthesis in old mice. *Arthritis Rheumatol.* **2020**. [[CrossRef](#)] [[PubMed](#)]
33. Zhang, Y.; Wei, Y.; Liu, D.; Liu, F.; Li, X.; Pan, L.; Pang, Y.; Chen, D. Role of growth differentiation factor 11 in development, physiology and disease. *Oncotarget* **2017**, *8*, 81604–81616. [[CrossRef](#)] [[PubMed](#)]
34. Grabowska, W.; Sikora, E.; Bielak-Zmijewska, A. Sirtuins, a promising target in slowing down the ageing process. *Biogerontology* **2017**, *18*, 447–476. [[CrossRef](#)] [[PubMed](#)]
35. Russomanno, G.; Corbi, G.; Manzo, V.; Ferrara, N.; Rengo, G.; Puca, A.A.; Latte, S.; Carrizzo, A.; Calabrese, M.C.; Andriantsitohaina, R.; et al. The anti-ageing molecule sirt1 mediates beneficial effects of cardiac rehabilitation. *Immun. Ageing* **2017**, *14*, 7. [[CrossRef](#)] [[PubMed](#)]

36. Chen, H.; Liu, X.; Zhu, W.; Hu, X.; Jiang, Z.; Xu, Y.; Wang, L.; Zhou, Y.; Chen, P.; Zhang, N.; et al. SIRT1 ameliorates age-related senescence of mesenchymal stem cells via modulating telomere shelterin. *Front. Aging Neurosci.* **2014**, *6*, 103. [[CrossRef](#)]
37. Waters, R.S.; Perry, J.S.A.; Han, S.; Bielekova, B.; Gedeon, T. The effects of interleukin-2 on immune response regulation. *Math. Med. Biol.* **2018**, *35*, 79–119. [[CrossRef](#)]
38. Ross, S.H.; Cantrell, D.A. Signaling and Function of Interleukin-2 in T Lymphocytes. *Annu. Rev. Immunol.* **2018**, *36*, 411–433. [[CrossRef](#)]
39. Chinen, T.; Kannan, A.K.; Levine, A.G.; Fan, X.; Klein, U.; Zheng, Y.; Gasteiger, G.; Feng, Y.; Fontenot, J.D.; Rudensky, A.Y. An essential role for the IL-2 receptor in Treg cell function. *Nat. Immunol.* **2016**, *17*, 1322–1333. [[CrossRef](#)]
40. Fan, M.Y.; Low, J.S.; Tanimine, N.; Finn, K.K.; Priyadharshini, B.; Germana, S.K.; Kaech, S.M.; Turka, L.A. Differential Roles of IL-2 Signaling in Developing versus Mature Tregs. *Cell Rep.* **2018**, *25*, 1204–1213. [[CrossRef](#)]
41. Tang, Q. Therapeutic window of interleukin-2 for autoimmune diseases. *Diabetes* **2015**, *64*, 1912–1913. [[CrossRef](#)] [[PubMed](#)]
42. Zhang, M.; Tang, Q. Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation. *Immunotherapy* **2015**, *7*, 1231–1234. [[CrossRef](#)] [[PubMed](#)]
43. Zenobia, C.; Hajishengallis, G. Basic biology and role of interleukin-17 in immunity and inflammation. *Periodontol 2000* **2015**, *69*, 142–159. [[CrossRef](#)] [[PubMed](#)]
44. Mysliwska, J.; Bryl, E.; Foerster, J.; Mysliwski, A. Increase of interleukin 6 and decrease of interleukin 2 production during the ageing process are influenced by the health status. *Mech. Ageing Dev.* **1998**, *100*, 313–328. [[CrossRef](#)]
45. Ouyang, X.; Yang, Z.; Zhang, R.; Arnaboldi, P.; Lu, G.; Li, Q.; Wang, W.; Zhang, B.; Cui, M.; Zhang, H.; et al. Potentiation of Th17 cytokines in aging process contributes to the development of colitis. *Cell. Immunol.* **2011**, *266*, 208–217. [[CrossRef](#)]
46. Gillis, S.; Kozak, R.; Durante, M.; Weksler, M.E. Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. *J. Clin. Investig.* **1981**, *67*, 937–942. [[CrossRef](#)]
47. Li, M.; Yao, D.; Zeng, X.; Kasakovski, D.; Zhang, Y.; Chen, S.; Zha, X.; Li, Y.; Xu, L. Age related human T cell subset evolution and senescence. *Immun. Ageing* **2019**, *16*, 24. [[CrossRef](#)]
48. Qin, L.; Jing, X.; Qiu, Z.; Cao, W.; Jiao, Y.; Routy, J.P.; Li, T. Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. *Ageing (Albany NY)* **2016**, *8*, 848–859. [[CrossRef](#)]
49. Gounder, S.S.; Abdullah, B.J.J.; Radzuanb, N.; Zain, F.; Sait, N.B.M.; Chua, C.; Subramani, B. Effect of Aging on NK Cell Population and Their Proliferation at Ex Vivo Culture Condition. *Anal. Cell. Pathol. (Amst)* **2018**, *2018*, 7871814. [[CrossRef](#)]
50. Solana, R.; Campos, C.; Pera, A.; Tarazona, R. Shaping of NK cell subsets by aging. *Curr. Opin. Immunol.* **2014**, *29*, 56–61. [[CrossRef](#)]
51. Komai, T.; Inoue, M.; Okamura, T.; Morita, K.; Iwasaki, Y.; Sumitomo, S.; Shoda, H.; Yamamoto, K.; Fujio, K. Transforming Growth Factor-beta and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals. *Front. Immunol.* **2018**, *9*, 1364. [[CrossRef](#)] [[PubMed](#)]
52. Hsu, P.; Santner-Nanan, B.; Hu, M.; Skarratt, K.; Lee, C.H.; Stormon, M.; Wong, M.; Fuller, S.J.; Nanan, R. IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1. *J. Immunol.* **2015**, *195*, 3665–3674. [[CrossRef](#)] [[PubMed](#)]
53. Martin-Moreno, P.L.; Tripathi, S.; Chandraker, A. Regulatory T Cells and Kidney Transplantation. *Clin. J. Am. Soc. Nephrol.* **2018**, *13*, 1760–1764. [[CrossRef](#)] [[PubMed](#)]
54. Lerner, A.; Yamada, T.; Miller, R.A. Pgp-1hi T lymphocytes accumulate with age in mice and respond poorly to concanavalin A. *Eur. J. Immunol.* **1989**, *19*, 977–982. [[CrossRef](#)]
55. Lefebvre, J.S.; Haynes, L. Aging of the CD4 T Cell Compartment. *Open Longev. Sci.* **2012**, *6*, 83–91. [[CrossRef](#)]
56. Baek, K.S.; Yi, Y.S.; Son, Y.J.; Yoo, S.; Sung, N.Y.; Kim, Y.; Hong, S.; Aravinthan, A.; Kim, J.H.; Cho, J.Y. In vitro and in vivo anti-inflammatory activities of Korean Red Ginseng-derived components. *J. Ginseng Res.* **2016**, *40*, 437–444. [[CrossRef](#)]

57. Yu, T.; Rhee, M.H.; Lee, J.; Kim, S.H.; Yang, Y.; Kim, H.G.; Kim, Y.; Kim, C.; Kwak, Y.S.; Kim, J.H.; et al. Ginsenoside Rc from Korean Red Ginseng (*Panax ginseng* C.A. Meyer) Attenuates Inflammatory Symptoms of Gastritis, Hepatitis and Arthritis. *Am. J. Chin. Med.* **2016**, *44*, 595–615. [[CrossRef](#)]
58. Yang, Y.; Yang, W.S.; Yu, T.; Sung, G.H.; Park, K.W.; Yoon, K.; Son, Y.J.; Hwang, H.; Kwak, Y.S.; Lee, C.M.; et al. ATF-2/CREB/IRF-3-targeted anti-inflammatory activity of Korean red ginseng water extract. *J. Ethnopharmacol.* **2014**, *154*, 218–228. [[CrossRef](#)]
59. Anisimov, V.N. Metformin: Do we finally have an anti-aging drug? *Cell Cycle* **2013**, *12*, 3483–3489. [[CrossRef](#)]
60. Kinaan, M.; Ding, H.; Triggle, C.R. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. *Med. Princ. Pract.* **2015**, *24*, 401–415. [[CrossRef](#)]
61. Xu, Q.; Ming, Z.; Dart, A.M.; Du, X.J. Optimizing dosage of ketamine and xylazine in murine echocardiography. *Clin. Exp. Pharmacol. Physiol.* **2007**, *34*, 499–507. [[CrossRef](#)] [[PubMed](#)]
62. Han, S.Y.; Yi, Y.S.; Jeong, S.G.; Hong, Y.H.; Choi, K.J.; Hossain, M.A.; Hwang, H.; Rho, H.S.; Lee, J.; Kim, J.H.; et al. Ethanol Extract of Liliun Bulbs Plays an Anti-Inflammatory Role by Targeting the IKK[Formula: See text]/[Formula: See text]-Mediated NF-[Formula: See text]B Pathway in Macrophages. *Am. J. Chin. Med.* **2018**, *46*, 1281–1296. [[CrossRef](#)] [[PubMed](#)]
63. Hwang, S.H.; Lorz, L.R.; Yi, D.K.; Noh, J.K.; Yi, Y.S.; Cho, J.Y. *Viburnum pichinchense* methanol extract exerts anti-inflammatory effects via targeting the NF-kappaB and caspase-11 non-canonical inflammasome pathways in macrophages. *J. Ethnopharmacol.* **2019**, *245*, 112161. [[CrossRef](#)] [[PubMed](#)]

**Sample Availability:** Samples of the compounds, Korean red ginseng, are available from the authors.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).